Double minute chromosomes and c-MYC amplification in a child with secondary myelodysplastic syndrome after treatment for acute lymphoblastic leukemia.
S
S
Mathew
R B
RB
Lorsbach
P
P
Shearer
J T
JT
Sandlund
S C
SC
Raimondi
D000754:Anemia, Refractory, with Excess of Blasts / Q000139:chemically induced / Q000188:drug therapy / Q000209:etiology* / Q000235:genetics; D000782:Aneuploidy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D002869:Chromosome Aberrations; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics*; D017338:Cladribine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D016371:Cranial Irradiation / Q000009:adverse effects*; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D017809:Fatal Outcome; D005260:Female; D005784:Gene Amplification; D016259:Genes, myc; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage / Q000009:adverse effects; D007621:Karyotyping; D015122:Mercaptopurine / Q000008:administration & dosage / Q000009:adverse effects; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D003561:Cytarabine; D017338:Cladribine; D014750:Vincristine; D015122:Mercaptopurine; D001215:Asparaginase; D011241:Prednisone; D006854:Hydrocortisone; D003630:Daunorubicin